<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02142010</url>
  </required_header>
  <id_info>
    <org_study_id>LY-TM-LPS-2014-01</org_study_id>
    <nct_id>NCT02142010</nct_id>
  </id_info>
  <brief_title>Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pathological complete response (pCR) rate in
      breast cancer patients treated with weekly paclitaxel liposome injection plus cisplatin
      preoperative regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete remission (pCR) rate</measure>
    <time_frame>after 4 months of preoperative treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>4 months during neoadjuvant therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>after 4 months of preoperative therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel liposome injection plus cisplatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel liposome injection plus cisplatin</intervention_name>
    <description>Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)</description>
    <arm_group_label>paclitaxel liposome injection plus cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged ≥ 18 years and &lt; 65 years,An estimated life expectancy of at least 12
             months

          -  ECOG 0-1

          -  At least one measurable disease according to the RECIST. histologically confirmed
             invasive breast cancer, stage II and III, no prior systemic or loco-regional treatment
             of breast cancer

          -  Biopsy specimens are available for ER, PgR and Her2 analysis

          -  Adequate bone marrow function: Neutrophil ≥ 1.5*109/L; Hb ≥ 100g/L; PLT ≥ 100*109/L

          -  adequate liver function (bilirubin &gt; 1.0 times upper normal limit [UNL] and ALT and/or
             AST&gt; 1.5 UNL associated with alkaline phosphatase &gt; 2.5 UNL;

          -  Women with potential child-bearing must have a negative pregnancy test (urine or
             serum) within 7 days of drug administration and agree to use an acceptable method of
             birth control to avoid pregnancy for the duration of the study

          -  No obvious main organs dysfunction

          -  patients must be accessible for treatment and follow-up and written informed consent

        Exclusion Criteria:

          -  Patient is pregnant or breast feeding

          -  Inflammatory breast cancer and Metastatic breast cancer

          -  Patients with medical conditions that indicate intolerant to neoadjuvant therapy and
             related treatment, including uncontrolled pulmonary disease, diabetes mellitis, severe
             infection, active peptic ulcer, coagulation disorder, connective tissue disease or
             myelo-suppressive disease

          -  History of congestive heart failure, uncontrolled or symptomatic angina pectoris,
             arrhythmia or myocardial infarction; poorly controlled hypertension (systolic BP &gt; 180
             mmHg or diastolic BP &gt; 100 mmHg)

          -  Has peripheral neuropathy

          -  Treatment with any investigational drugs within 30 days before the beginning of study
             treatment

          -  No psychiatric illness and other situations that would limit compliance of study

          -  With a history of other malignant tumor

          -  Known severe hypersensitivity to any drugs in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinsong Lu, MD</last_name>
    <email>lujjss@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine, Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinsong Lu, MD</last_name>
      <email>lujjss@126.com</email>
    </contact>
    <investigator>
      <last_name>Jinsong Lu, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

